BioSpace News Archive

Orphazyme A/S in restructuring, a late-stage biopharmaceutical company, announces that following the Company’s voluntary delisting of the Company’s American Depositary Shares representing its ordinary shares from Nasdaq Global Select Market has become effective on March 31, 2022.

Timber Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, provided a business update and announced financial results for the fourth quarter and year ended December 31, 2021.

SELLAS Life Sciences Group, Inc. announced the pricing of its previously announced underwritten public offering of 4,629,630 shares of its common stock and accompanying warrants to purchase up to 4,629,630 shares of common stock at a combined public offering price of $5.40 per share and accompanying warrant.

On March 31, 2022, Venus Medtech Inc., a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its annual results for the year ended December 31, 2021.

Statera Biopharma, Inc. announced that the Company has filed a Form 12b-25 with the U.S. Securities and Exchange Commission to extend until April 15, 2022 the due date for filing the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced financial results for the year ended December 31, 2021.

SELLAS Life Sciences Group, Inc. and GenFleet Therapeutics, Inc. announced that the companies have entered into an exclusive license agreement that grants rights to SELLAS for the development and commercialization of GFH009, a highly selective small molecule cyclin-dependent kinase 9 inhibitor, across all therapeutic and diagnostic uses worldwide outside of Greater China.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock.

The Gastric Cancer Foundation has announced the launch of its 2022 grant program.

epipole, an emerging provider of world-class handheld fundus cameras, announced the global launch of their new epiCam fundus camera to the US Eye Care market, at the Vision Expo East in New York City.